After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
The new online Learning Center with new content can still be found under the “Training” folder on ...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...